Meredith Corporation MDP
Set alert
59.07 0.00 0.00%
At close · Dec 1
59.04 Day range 59.13
52-week range unavailable
- Open
- 59.10
- Prev close
- 59.07
- Mkt cap
- 2.71B
- Vol
- 3.36M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 59.04
- High
- 59.13
- Forward P/E
- 9.24
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- Oct 28, 2021
- 50-d avg
- 57.94
- 200-d avg
- 42.90
- 1y target
- 53.00
Key statistics
- Market cap
- 2.71B
- Trailing P/E
- 10.05
- Forward P/E
- 9.24
- Price / sales
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- 50-day average
- 57.94
- 200-day average
- 42.90
Analyst view
Consensus: hold
Hold
Price target (mean) 53.00 -10.3% downside
Now 59.07
- Target (low)
- 36.00
- Target (mean)
- 53.00
- Target (high)
- 59.00
Ratings (0m) 6 2 buy · 4 hold · 0 sell
- Strong buy1
- Buy1
- Hold4
- Sell0
- Strong sell0
Next earnings
Oct 28, 2021
Expected Oct 28, 2021. Consensus EPS estimate 2.05.
Financials — quick view
MDP Revenue — quarterly 708.60M
MDP Net income — quarterly 24.30M
MDP EPS — quarterly 0.52
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 28, 2021 | Sep 1, 2021 | 0.00 | — | — | — |
| Aug 12, 2021 | Jun 1, 2021 | 0.00 | — | — | — |
| Apr 29, 2021 | Mar 1, 2021 | 0.00 | — | — | — |
| Feb 4, 2021 | Dec 1, 2020 | 0.00 | — | — | — |
| Nov 5, 2020 | Sep 1, 2020 | 0.00 | — | — | — |
| Aug 13, 2020 | Jun 1, 2020 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 8, 2021 | Citigroup | down | Buy | Neutral |
| Aug 17, 2021 | Citigroup | main | — | Buy |
| Mar 1, 2021 | Benchmark | up | Hold | Buy |
| Aug 14, 2020 | Benchmark | down | Buy | Hold |
| Apr 9, 2020 | Citigroup | main | — | Buy |
| Nov 19, 2019 | Stephens & Co. | main | — | Equal-Weight |
News
- Medexus Eyes $175M GRAFAPEX Opportunity as Transplant Drug Gains Traction
- Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
- Private Equity Giant MDP Acquiring Marygold Companies
- Medexus Pharmaceuticals Q1 Earnings Call Highlights
- Credit Card Balances at Pace with Inflation: Whitney
- Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2026 Conference Call
- The New York Times Company's President and Chief Executive Officer Meredith Kopit Levien to Participate in the J.P. Morgan Global Technology, Media and Communications Conference
- The New York Times Company's President and Chief Executive Officer Meredith Kopit Levien to Participate in the Morgan Stanley Technology, Media & Telecom Conference
- Medexus Pharmaceuticals Inc. (MDP:CA) Q3 2026 Earnings Call Transcript
- Medexus Pharmaceuticals (TSE:MDP) Trading Up 2.1% – What’s Next?
Your note
Sign in to keep a note on MDP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAER DONALD A | Director | Stock Award(Grant) | Nov 10, 2020 | 13,293 |
| BERG DONALD C | Director | Stock Award(Grant) | Nov 10, 2020 | 43,573 |
| CAPPAERT STEVEN M | Officer | Conversion of Exercise of derivative security | Aug 19, 2021 | 22,655 |
| FRAZIER DIANNA MEREDITH MELL | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Nov 10, 2020 | 24,339 |
| FRAZIER MEREDITH D MELL | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Nov 10, 2020 | 24,339 |
| HARTY THOMAS H | Chief Executive Officer | Conversion of Exercise of derivative security | Aug 19, 2021 | 100,144 |